Q-omics provides the consensus-scored LRRC70 profile across patient tissues and cancer cell-line models. LRRC70 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRRC70 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, LRRC70 RNA expression shows 19,189 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where LRRC70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC70 survival associations across molecular data types. LRRC70 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC70 RNA expression–survival associations across cancer types. High LRRC70 expression shows unfavorable associations in KIRP and SCLC, but favorable associations in KIRC, THCA, LIHC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRRC70 RNA expression.
This table summarizes LRRC70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC70 shows lower tumor expression in KICH, KIRP, LUSC, THCA, BLCA and LUAD. The KICH box plot shows higher LRRC70 RNA expression in normal versus tumor tissue (log2 FC = −1.380, t-test p < 0.001).
This table shows molecular features associated with LRRC70 in patient tissues and cancer cell lines. In patient samples, LRRC70 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC70 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
